Editas Medicine Stock Price, News & Analysis (NASDAQ:EDIT)

$35.89 +0.78 (+2.22 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$35.89
Today's Range$34.20 - $36.33
52-Week Range$13.12 - $41.60
Volume1.11 million shs
Average Volume1.61 million shs
Market Capitalization$1.59 billion
P/E Ratio-11.08
Dividend YieldN/A
Beta4.79

About Editas Medicine (NASDAQ:EDIT)

Editas Medicine logoEditas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000

Debt

Debt-to-Equity Ratio0.19%
Current Ratio10.12%
Quick Ratio10.12%

Price-To-Earnings

Trailing P/E Ratio-11.0771604938272
Forward P/E Ratio-12.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.05 million
Price / Sales269.09
Cash FlowN/A
Price / CashN/A
Book Value$3.67 per share
Price / Book9.78

Profitability

Trailing EPS($3.24)
Net Income$-97,180,000.00
Net Margins-1,127.03%
Return on Equity-70.19%
Return on Assets-37.08%

Miscellaneous

Employees89
Outstanding Shares45,360,000

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

How were Editas Medicine's earnings last quarter?

Editas Medicine Inc (NASDAQ:EDIT) released its earnings results on Tuesday, November, 7th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.04. The business earned $6.28 million during the quarter, compared to analysts' expectations of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The company's revenue for the quarter was up 553.0% compared to the same quarter last year. During the same period last year, the business earned ($0.59) earnings per share. View Editas Medicine's Earnings History.

When will Editas Medicine make its next earnings announcement?

Editas Medicine is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Editas Medicine.

Where is Editas Medicine's stock going? Where will Editas Medicine's stock price be in 2018?

9 brokerages have issued 12-month target prices for Editas Medicine's stock. Their predictions range from $27.00 to $45.00. On average, they anticipate Editas Medicine's stock price to reach $32.00 in the next year. View Analyst Ratings for Editas Medicine.

What are Wall Street analysts saying about Editas Medicine stock?

Here are some recent quotes from research analysts about Editas Medicine stock:

  • 1. Cann analysts commented, "Editas Medicine announced on February 16 the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. We believe Dr. Hopfield will bring significant commercial and operational experience to the Editas board." (2/16/2018)
  • 2. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (1/9/2018)

Who are some of Editas Medicine's key competitors?

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the folowing people:

  • Katrine S. Bosley, President, Chief Executive Officer, Director (Age 49)
  • Andrew A. F. Hack, Chief Financial Officer (Age 43)
  • Charles Albright, Chief Scientific Officer (Age 59)
  • Gerald Cox, Chief Medical Officer (Age 58)
  • Andrew Hirsch, Director (Age 46)
  • Jessica Hopfield Ph.D., Director (Age 52)
  • Akshay K. Vaishnaw M.D., Ph.D., Director (Age 54)
  • Kevin J. Bitterman Ph.D., Independent Director (Age 40)
  • Alexis Borisy, Independent Director (Age 45)

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who owns Editas Medicine stock?

Editas Medicine's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.89%), ARK Investment Management LLC (2.45%), Global Thematic Partners LLC (1.35%), Farallon Capital Management LLC (1.14%), Millennium Management LLC (0.93%) and TIAA CREF Investment Management LLC (0.81%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Gerald Frank Cox, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Who sold Editas Medicine stock? Who is selling Editas Medicine stock?

Editas Medicine's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Hudson Bay Capital Management LP, Metropolitan Life Insurance Co. NY, American Century Companies Inc. and Bank of New York Mellon Corp. Company insiders that have sold Editas Medicine company stock in the last year include Alexandra Glucksmann, Andrew A F Hack, Katrine Bosley and Kevin Bitterman. View Insider Buying and Selling for Editas Medicine.

Who bought Editas Medicine stock? Who is buying Editas Medicine stock?

Editas Medicine's stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, ARK Investment Management LLC, UBS Asset Management Americas Inc., Arrowstreet Capital Limited Partnership, Capital Advisors Inc. OK, TIAA CREF Investment Management LLC, Guggenheim Capital LLC and Geode Capital Management LLC. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic and Gerald Frank Cox. View Insider Buying and Selling for Editas Medicine.

How do I buy Editas Medicine stock?

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Editas Medicine's stock price today?

One share of Editas Medicine stock can currently be purchased for approximately $35.89.

How big of a company is Editas Medicine?

Editas Medicine has a market capitalization of $1.59 billion and generates $6.05 million in revenue each year. The company earns $-97,180,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. Editas Medicine employs 89 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


MarketBeat Community Rating for Editas Medicine (EDIT)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  291
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Editas Medicine (NASDAQ:EDIT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyHoldHold
Consensus Rating Score: 2.332.562.442.43
Ratings Breakdown: 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.00$32.60$27.00$26.33
Price Target Upside: 8.02% downside5.83% downside17.04% upside46.46% upside

Editas Medicine (NASDAQ:EDIT) Consensus Price Target History

Price Target History for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ:EDIT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018CannReiterated RatingHoldHighView Rating Details
2/13/2018CLSAInitiated CoverageUnderperform -> UnderperformLowView Rating Details
1/23/2018SunTrust BanksUpgradeHold -> Buy$17.00 -> $45.00HighView Rating Details
11/7/2017CowenReiterated RatingBuyN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$27.00 -> $28.00N/AView Rating Details
9/6/2017BarclaysInitiated CoverageOverweight$19.69 -> $28.00MediumView Rating Details
8/9/2017JPMorgan Chase & Co.Set Price TargetHold$27.00HighView Rating Details
7/18/2017OppenheimerMarket PerformN/AView Rating Details
3/27/2017Chardan CapitalInitiated CoverageBuy -> BuyHighView Rating Details
2/15/2017Jefferies GroupReiterated RatingBuy$35.00N/AView Rating Details
2/29/2016JMP SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Editas Medicine (NASDAQ:EDIT) Earnings History and Estimates Chart

Earnings by Quarter for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ EDIT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.75)N/AView Earnings Details
11/7/2017Q3 2017($0.60)($0.64)$2.66 million$6.28 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.64)($0.65)$2.20 million$3.10 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.62)($0.85)$1.00 million$0.68 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.62)($1.10)$1.11 million$0.90 millionViewListenView Earnings Details
11/7/2016Q3($0.64)($0.59)$1.00 million$1.00 millionViewListenView Earnings Details
8/9/2016Q2($0.54)($0.54)$3.52 million$3.39 millionViewListenView Earnings Details
5/16/2016Q116($0.23)($0.80)$1.08 million$0.80 millionViewListenView Earnings Details
3/30/2016Q4($0.52)($4.05)$0.79 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Editas Medicine (NASDAQ:EDIT) Earnings Estimates

2018 EPS Consensus Estimate: ($3.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.96)($0.70)($0.83)
Q2 20182($0.84)($0.72)($0.78)
Q3 20182($0.97)($0.74)($0.86)
Q4 20182($1.56)($0.76)($1.16)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Editas Medicine (NASDAQ:EDIT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Editas Medicine (NASDAQ EDIT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.40%
Institutional Ownership Percentage: 69.66%
Insider Trades by Quarter for Editas Medicine (NASDAQ:EDIT)
Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Editas Medicine (NASDAQ EDIT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Andrew A F HackCFOSell18,000$34.21$615,780.00View SEC Filing  
2/1/2018Katrine BosleyCEOSell8,333$36.18$301,487.941,338,898View SEC Filing  
1/30/2018Katrine BosleyInsiderSell20,000$38.79$775,800.001,354,431View SEC Filing  
1/23/2018Katrine BosleyInsiderSell3,338$35.28$117,764.641,364,431View SEC Filing  
1/3/2018Katrine BosleyInsiderSell14,995$34.15$512,079.25View SEC Filing  
12/19/2017Andrew A F HackCFOSell14,649$24.68$361,537.325,000View SEC Filing  
12/15/2017Andrew A F HackCFOSell5,000$24.31$121,550.005,000View SEC Filing  
12/1/2017Katrine BosleyInsiderSell8,333$29.58$246,490.141,387,897View SEC Filing  
11/20/2017Andrew A F HackCFOSell5,000$25.35$126,750.005,000View SEC Filing  
11/17/2017Andrew A F HackCFOSell5,000$24.81$124,050.005,000View SEC Filing  
11/1/2017Katrine BosleyInsiderSell8,333$23.64$196,992.121,393,322View SEC Filing  
10/2/2017Katrine BosleyInsiderSell8,333$24.78$206,491.74View SEC Filing  
9/5/2017Katrine BosleyInsiderSell16,666$20.33$338,819.781,414,629View SEC Filing  
9/1/2017Katrine BosleyCEOSell10,000$20.42$204,200.001,414,629View SEC Filing  
8/11/2017Katrine BosleyInsiderSell16,666$20.02$333,653.321,431,095View SEC Filing  
6/2/2017Boris NikolicDirectorBuy35,000$14.07$492,450.0035,000View SEC Filing  
6/2/2017Gerald Frank CoxInsiderBuy4,000$14.15$56,600.004,000View SEC Filing  
5/22/2017Kevin BittermanDirectorSell1,000,000$17.00$17,000,000.00View SEC Filing  
3/15/2017Alexandra GlucksmannCOOSell1,000$26.41$26,410.00118,788View SEC Filing  
2/15/2017Alexandra GlucksmannCOOSell6,000$20.58$123,480.00123,788View SEC Filing  
2/15/2017Andrew A F HackCFOSell3,000$19.20$57,600.003,000View SEC Filing  
1/11/2017Andrew A F HackCFOSell15,000$19.20$288,000.0015,000View SEC Filing  
12/7/2016Polaris Venture Management Co.Major ShareholderSell75,000$15.82$1,186,500.00View SEC Filing  
12/6/2016Kevin BittermanDirectorSell130,000$15.79$2,052,700.00View SEC Filing  
11/23/2016Kevin BittermanDirectorSell21,480$15.71$337,450.80View SEC Filing  
11/22/2016Polaris Venture Management Co.Major ShareholderSell12,819$15.77$202,155.63View SEC Filing  
11/15/2016Kevin BittermanDirectorSell88,900$16.96$1,507,744.00View SEC Filing  
9/8/2016Polaris Venture Management Co.Major ShareholderSell500,000$16.80$8,400,000.00View SEC Filing  
9/6/2016Kevin P. StarrMajor ShareholderSell5,890$15.90$93,651.00View SEC Filing  
8/23/2016Alexandra GlucksmannCOOSell1,000$20.00$20,000.00118,788View SEC Filing  
2/8/2016James E FlynnInsiderBuy100,000$16.00$1,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Editas Medicine (NASDAQ EDIT) News Headlines

Source:
DateHeadline
Orgenesis (ORGS): An Undervalued Small Cap Biotech Company Every Healthcare Investor Should Know AboutOrgenesis (ORGS): An Undervalued Small Cap Biotech Company Every Healthcare Investor Should Know About
finance.yahoo.com - February 23 at 8:29 AM
Editas Medicine Inc (EDIT) Given Average Recommendation of "Hold" by BrokeragesEditas Medicine Inc (EDIT) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 22 at 1:24 AM
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors - GlobeNewswire (press release)Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors - GlobeNewswire (press release)
globenewswire.com - February 17 at 8:00 AM
Andrew A. F. Hack Sells 18,000 Shares of Editas Medicine Inc (EDIT) StockAndrew A. F. Hack Sells 18,000 Shares of Editas Medicine Inc (EDIT) Stock
www.americanbankingnews.com - February 16 at 9:46 PM
Editas Medicine Names Jessica Hopfield, Ph.D., to Board of DirectorsEditas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors
finance.yahoo.com - February 16 at 5:30 PM
Editas Medicine (EDIT) Receives Hold Rating from CannEditas Medicine (EDIT) Receives Hold Rating from Cann
www.americanbankingnews.com - February 16 at 4:20 PM
Form SC 13G Editas Medicine, Inc. Filed by: STATE STREET CORP - StreetInsider.comForm SC 13G Editas Medicine, Inc. Filed by: STATE STREET CORP - StreetInsider.com
www.streetinsider.com - February 15 at 7:24 AM
Editas Medicine Inc (EDIT) Expected to Announce Quarterly Sales of $3.33 MillionEditas Medicine Inc (EDIT) Expected to Announce Quarterly Sales of $3.33 Million
www.americanbankingnews.com - February 14 at 12:38 PM
CLSA Initiates Coverage on Editas Medicine (EDIT)CLSA Initiates Coverage on Editas Medicine (EDIT)
www.americanbankingnews.com - February 13 at 11:32 AM
Analyzing Enanta Pharmaceuticals (ENTA) and Editas Medicine (EDIT)Analyzing Enanta Pharmaceuticals (ENTA) and Editas Medicine (EDIT)
www.americanbankingnews.com - February 12 at 3:14 PM
Zacks: Analysts Expect Editas Medicine Inc (EDIT) to Announce -$0.79 Earnings Per ShareZacks: Analysts Expect Editas Medicine Inc (EDIT) to Announce -$0.79 Earnings Per Share
www.americanbankingnews.com - February 12 at 7:38 AM
Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - February 9 at 7:24 AM
Editas Medicine to Participate in Upcoming Investor ConferencesEditas Medicine to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 9 at 7:24 AM
Editas Medicine Inc (EDIT) CEO Sells $301,487.94 in StockEditas Medicine Inc (EDIT) CEO Sells $301,487.94 in Stock
www.americanbankingnews.com - February 5 at 6:44 PM
Analyzing PAREXEL International (PRXL) & Editas Medicine (EDIT)Analyzing PAREXEL International (PRXL) & Editas Medicine (EDIT)
www.americanbankingnews.com - February 5 at 11:06 AM
All the Stocks I'm Selling If the Market Keeps FallingAll the Stocks I'm Selling If the Market Keeps Falling
finance.yahoo.com - February 5 at 7:24 AM
Can CRISPR And 3 Small Biotech Companies Cure 10,000 Diseases?Can CRISPR And 3 Small Biotech Companies Cure 10,000 Diseases?
finance.yahoo.com - February 1 at 3:28 PM
Arena Pharmaceuticals (ARNA) vs. Editas Medicine (EDIT) Critical ComparisonArena Pharmaceuticals (ARNA) vs. Editas Medicine (EDIT) Critical Comparison
www.americanbankingnews.com - January 31 at 11:12 PM
Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 20,000 SharesEditas Medicine Inc (EDIT) Insider Katrine Bosley Sells 20,000 Shares
www.americanbankingnews.com - January 31 at 6:24 PM
Editas Medicine (EDIT) Surges: Stock Moves 13.2% Higher - NasdaqEditas Medicine (EDIT) Surges: Stock Moves 13.2% Higher - Nasdaq
www.nasdaq.com - January 30 at 3:29 PM
Here's Why Editas Medicine Rose as Much as 15.7% YesterdayHere's Why Editas Medicine Rose as Much as 15.7% Yesterday
finance.yahoo.com - January 30 at 3:29 PM
Editas Medicine (EDIT) Surges: Stock Moves 13.2% HigherEditas Medicine (EDIT) Surges: Stock Moves 13.2% Higher
finance.yahoo.com - January 30 at 3:29 PM
Editas Medicine Inc (EDIT) Given Consensus Rating of "Hold" by AnalystsEditas Medicine Inc (EDIT) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - January 28 at 1:34 AM
Investors Buy High Volume of Call Options on Editas Medicine (EDIT)Investors Buy High Volume of Call Options on Editas Medicine (EDIT)
www.americanbankingnews.com - January 27 at 3:16 AM
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration - GlobeNewswire (press release)Adverum Biotechnologies and Editas Medicine Extend Research Collaboration - GlobeNewswire (press release)
globenewswire.com - January 26 at 7:13 AM
Adverum Biotechnologies and Editas Medicine Extend Research CollaborationAdverum Biotechnologies and Editas Medicine Extend Research Collaboration
finance.yahoo.com - January 26 at 7:13 AM
Insider Selling: Editas Medicine Inc (EDIT) Insider Sells 3,338 Shares of StockInsider Selling: Editas Medicine Inc (EDIT) Insider Sells 3,338 Shares of Stock
www.americanbankingnews.com - January 25 at 9:44 PM
Equities Analysts Set Expectations for Editas Medicine Incs FY2019 Earnings (EDIT)Equities Analysts Set Expectations for Editas Medicine Inc's FY2019 Earnings (EDIT)
www.americanbankingnews.com - January 25 at 3:28 PM
Analysts Set Expectations for Editas Medicine Incs FY2022 Earnings (EDIT)Analysts Set Expectations for Editas Medicine Inc's FY2022 Earnings (EDIT)
www.americanbankingnews.com - January 24 at 9:02 PM
2 Gene Editing Stocks SunTrust Recommends - Benzinga2 Gene Editing Stocks SunTrust Recommends - Benzinga
www.benzinga.com - January 24 at 5:31 AM
2 Gene Editing Stocks SunTrust Recommends2 Gene Editing Stocks SunTrust Recommends
finance.yahoo.com - January 24 at 5:31 AM
Here's Why Editas Medicine Gained as Much as 14.2% TodayHere's Why Editas Medicine Gained as Much as 14.2% Today
finance.yahoo.com - January 23 at 1:40 PM
 Brokerages Expect Editas Medicine Inc (EDIT) Will Announce Quarterly Sales of $3.33 Million Brokerages Expect Editas Medicine Inc (EDIT) Will Announce Quarterly Sales of $3.33 Million
www.americanbankingnews.com - January 11 at 1:58 PM
Editas Medicine Reports on Recent Progress and Announces ... - GlobeNewswire (press release)Editas Medicine Reports on Recent Progress and Announces ... - GlobeNewswire (press release)
globenewswire.com - January 9 at 9:42 AM
Stock Review for Biotechs Investors -- Editas Medicine, Illumina, Tesaro, and Endocyte - PR Newswire (press release)Stock Review for Biotech's Investors -- Editas Medicine, Illumina, Tesaro, and Endocyte - PR Newswire (press release)
www.prnewswire.com - January 9 at 9:42 AM
Editas lower on questions about Crispr efficacyEditas lower on questions about Crispr efficacy
finance.yahoo.com - January 8 at 5:14 PM
3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy?3 Soaring Gene-Editing Biotech Stocks: Which Is the Best Buy?
finance.yahoo.com - January 8 at 9:41 AM
What Should We Expect From Editas Medicine Inc’s (NASDAQ:EDIT) Earnings In The Years Ahead?What Should We Expect From Editas Medicine Inc’s (NASDAQ:EDIT) Earnings In The Years Ahead?
finance.yahoo.com - January 8 at 9:41 AM
Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare ConferenceEditas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 9:41 AM
Editas Medicine Reaches Analyst Target Price - NasdaqEditas Medicine Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - January 5 at 4:56 PM
Editas Medicine Inc (EDIT) Insider Sells $512,079.25 in StockEditas Medicine Inc (EDIT) Insider Sells $512,079.25 in Stock
www.americanbankingnews.com - January 4 at 7:32 PM
Editas Medicine to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Editas Medicine to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 4 at 9:39 AM
Is This Why Editas Medicine Is Surging Today? - Motley FoolIs This Why Editas Medicine Is Surging Today? - Motley Fool
www.fool.com - January 4 at 9:39 AM
Editas Medicine Inc (EDIT) Receives Consensus Recommendation of "Hold" from BrokeragesEditas Medicine Inc (EDIT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 3 at 1:58 AM
INSY On A High, KIDS Making Giant Strides, No Stopping APVO, EDIT UncutINSY On A High, KIDS Making Giant Strides, No Stopping APVO, EDIT Uncut
www.nasdaq.com - January 2 at 11:27 PM
Is This Why Editas Medicine Is Surging Today?Is This Why Editas Medicine Is Surging Today?
finance.yahoo.com - January 2 at 6:25 PM
Editas Medicine (EDIT) versus OptiNose (OPTN) Head to Head ReviewEditas Medicine (EDIT) versus OptiNose (OPTN) Head to Head Review
www.americanbankingnews.com - December 31 at 11:14 PM
Editas Medicine (EDIT) Lifted to Buy at BidaskClubEditas Medicine (EDIT) Lifted to Buy at BidaskClub
www.americanbankingnews.com - December 28 at 4:56 PM
Want To Invest In Editas Medicine Inc (NASDAQ:EDIT)? Here’s How It Performed LatelyWant To Invest In Editas Medicine Inc (NASDAQ:EDIT)? Here’s How It Performed Lately
finance.yahoo.com - December 28 at 3:48 PM
 Brokerages Expect Editas Medicine Inc (EDIT) to Post -$0.79 EPS Brokerages Expect Editas Medicine Inc (EDIT) to Post -$0.79 EPS
www.americanbankingnews.com - December 23 at 9:20 PM

SEC Filings

Editas Medicine (NASDAQ:EDIT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Editas Medicine (NASDAQ:EDIT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Editas Medicine (NASDAQ EDIT) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.